Navigation Links
EntreMed to Present at BIO CEO and Investor Conference
Date:2/5/2008

ROCKVILLE, Md., Feb. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the BIO CEO and Investor Conference, to be held at the Waldorf-Astoria Hotel, February 11-13, 2008. Mr. Burns' presentation is scheduled for Tuesday, February 12, 2008 at 2:45 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns' live presentation will be web cast and can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &

Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. EntreMed Appoints Senior Vice President of Research and Development
4. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
5. Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
10. inVentiv Health to Present at the 2008 UBS Global Healthcare Services Conference
11. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its ... in the learning technologies industry, Mastin joins NetDimensions from the New York office of ... At LEO, Mastin served as SVP of the North America offices and prior to ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq Technology , a ... that Chief Executive Officer (CEO) Debbie Gustafson has been appointed to the SEMI ... association connecting the electronics manufacturing supply chain. The mission of the SEMI NAAB ...
(Date:4/20/2017)... Minneapolis, MN and Bethesda, MD (PRWEB) , ... ... ... for Advancing Innovation announce the formation of a unique intellectual property (IP) sharing ... commercialization potential of their most promising inventions. A main component of this effort ...
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
Breaking Biology Technology:
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... Mar. 23, 2017 Research and Markets has ... Analysis & Trends - Industry Forecast to 2025" report to ... ... a CAGR of around 8.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
Breaking Biology News(10 mins):